: Incyte shares drop after FDA approves GSK’s competing blood-cancer treatment


Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that will compete with Incyte’s Jakafi. The FDA approved Ojjaara for use in patients with myelofibrosis, a rare blood cancer, with anemia. Ojjaara will likely put pressure on uptake of Jakafi as a first-line treatment for myelofibrosis, Truist Securities analysts wrote in a note Friday. The analysts maintained their buy rating on Incyte shares, saying they don’t anticipate that Ojjaara will impact Jakafi revenues from two other conditions, polycythemia vera and graft-versus-host disease. Incyte shares have dropped more than 22% in the year to date, while the S&P 500 has gained 15.9%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleMovers & Shakers: PayPal and Dropbox stocks fall after downgrades, GM shares inch higher, and more stocks on the move
Next articleU.S. News college rankings: Duke up, UChicago down — and Princeton is No. 1


Please enter your comment!
Please enter your name here